Our results may suggest that adding drugs which influence Rho-ROCK-JNK axis to the induction therapy could improve outcomes, especially in the group of patients with high level of gamma 1 actin at the time of diagnosis of AML. This evidence concerns the gene MAPK8 and acute myeloid leukemia.